首页> 外文期刊>Poiesis & praxis >Polymorphism-screening: genetic testing for predisposition—guidance for technology assessment
【24h】

Polymorphism-screening: genetic testing for predisposition—guidance for technology assessment

机译:多态性筛选:易感性的基因检测—技术评估指南

获取原文
获取原文并翻译 | 示例
       

摘要

Health policy is increasingly confronted with the demand for financing genetic testing on inherited susceptibility to disease. Tests on polymorphism/SNP associated with multicausal and chronic conditions are already offered in private commercial institutions or in academic hospitals. The increasing pressure on public health services to offer SNP testing leads to first methodological approaches for a generally valid regulatory framework applicable for inclusion or refusal of genetic tests into the public health services. Systematic search in Medline, Embase and the Web for methodological papers or guidelines for the assessment of polymorphism-screening. Since genetic testing has not only clinical and economic effects on health care, but also primarily ethical consequences by profiling our understanding of "health" and "disease", this paper gives an overview of relevant aspects and background information to consider in the assessment of genetic tests. Although 2-3 million SNPs are identified and the journals are full of reported "significant" associations between disease and mutation, only a few can be replicated unequivocally. The ACCE (Analytic and Clinical Validity, Clinical utility; Ethical, legal and social implications)-framework was developed by the Center of Disease Control for the assessment of genetic testing. This standardised appraisal approach proposes collecting and evaluating: (a) Prevalence, genotype-/phenotype-relation. (b) Clinical presentation: natural history; the different expressions of disease, (c) Performance of the genetic test, (d) Implications for therapy and prevention, (e) Conclusion for clinical applications of risk-profiling of health on their susceptibility to disease and/ or for clarification of disease for therapy planning. Since genetic testing is urging its way into the health care system, the actual danger is, that population screening starts before valid evidence from big prospective studies have been carried out and delivered proofs of direct causal associations. Before diffus ing into the health care system we are suggesting to take a cautious and standardised approach.
机译:卫生政策日益面临为遗传性疾病易感性进行基因检测的资金需求。私人商业机构或学术医院已经提供了与多因和慢性病相关的多态性/ SNP测试。公共卫生服务提供SNP检测的压力与日俱增,这导致首先采用方法论方法建立了适用于将基因检测纳入公共卫生服务或拒绝将其纳入公共卫生服务的普遍有效的监管框架。在Medline,Embase和Web上系统地搜索方法学论文或评估多态性筛选的指南。由于基因测试不仅对医疗保健产生了临床和经济影响,而且通过描述我们对“健康”和“疾病”的了解而主要具有伦理后果,因此本文概述了在评估遗传基因时应考虑的相关方面和背景信息测试。尽管已识别出2-3百万个SNP,并且期刊中已报道了疾病和突变之间的“重要”关联,但只有少数可以明确复制。 ACCE(分析和临床有效性,临床效用;伦理,法律和社会影响)框架是由疾病控制中心开发的,用于评估基因检测。这种标准化的评估方法建议收集和评估:(a)患病率,基因型/表型关系。 (b)临床表现:自然病史;疾病的不同表现形式,(c)基因测试的性能,(d)治疗和预防的意义,(e)关于对疾病易感性进行健康风险分析和/或阐明疾病的临床风险结论治疗计划。由于基因测试正在敦促进入卫生保健系统,因此实际的危险是,在进行来自大型前瞻性研究的有效证据并提供直接因果关系的证据之前,应开始进行人群筛查。在推广到医疗保健系统之前,我们建议采取谨慎和标准化的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号